Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

EQRx, Inc. - Common Stock (NQ: EQRX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about EQRx, Inc. - Common Stock

< Previous 1 2 3 Next >
EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX
From Kahn Swick & Foti, LLC
Via Business Wire
EQRX Shareholder Investigation: Robbins LLP Reminds Shareholders it is Investigating EQRx, Inc. on behalf of Shareholders
From Robbins LLP
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capri Holdings Limited (NYSE – CPRI), Avid® (Nasdaq - AVID), EQRx, Inc. (Nasdaq - EQRX)
From Brodsky & Smith LLC
Via GlobeNewswire
Earnings Outlook For EQRx
Via Benzinga
Why EQRx Shares Dropped 28.62% on Thursday
The company suspended trials for one of its lead therapies. 
Via The Motley Fool
EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX
From Kahn Swick & Foti, LLC
Via Business Wire
Why Aaron's Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) shares gained 188.8% to $4.13. The stock is now on the Regulation SHO "threshold security" list. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Revolution Medicines To Acquire EQRx In All-Stock Transaction To Gain Over $1B In Additional Capital
Revolution Medicines Inc (NASDAQ: RVMD) has agreed to acquire EQRx Inc (NASDAQ: EQRX) in an all-stock transaction intended to add more than $1 billion in net cash to  
Via Benzinga
Caterpillar, Oshkosh, AudioCodes And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Nasdaq Composite falling around 70 points on Tuesday. Here are some big stocks recording gains in today’s session. American Superconductor Corporation (NASDAQ: AMSC)... 
Via Benzinga
EQRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of EQRx, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital
From Revolution Medicines, Inc.; EQRx, Inc.
Via GlobeNewswire
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr.... 
Via Talk Markets
EQRx Announces Massive Strategic Reset, Slashes Pipeline & Workforce
EQRx Inc (NASDAQ: EQRX) will lay off 170 people and incur non-recurring costs of approximately $45 - $55 million for wind down, termination,  
Via Benzinga
EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results
From EQRx, Inc.
Via GlobeNewswire
EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023
From EQRx, Inc.
Via GlobeNewswire
EQRx, Inc. (EQRX) Shareholder Investigation: Robbins LLP is Investigating EQRX, Inc. on behalf of Shareholders
From Robbins LLP
Via Business Wire
EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress
From EQRx, Inc.
Via GlobeNewswire
EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
From EQRx, Inc.
Via GlobeNewswire
EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung Cancer
From EQRx, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 115 stocks hit new 52-week lows. 
Via Benzinga
EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
From EQRx, Inc.
Via GlobeNewswire
Week In Review: Insilico Signs Six-Drug Discovery Deal With Sanofi Worth Up To $1.2 Billion
Insilico Medicine signed a six-drug research collaboration with Sanofi that could be worth up to $1.2 billion. Insilico will receive up to $21.5 million in upfront and target nomination fees for each... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2022
Upgrades 
Via Benzinga
BP To Rally Around 22%? Plus This Analyst Predicts $47 For YETI
  Piper Sandler boosted the price target on BP p.l.c. (NYSE: BP) from $37 to $40. BP shares rose 1.9% to close at $32.95 on Thursday. 
Via Benzinga
Why Magnite Shares Are Trading Higher By Over 45%? Here Are 69 Stocks Moving In Thursday's Mid-Day Session
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares climbed 172% to $0.2769 after dipping 40% on Wednesday. Fast Radius received Bankruptcy court approval of first day motions related to the company's... 
Via Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Cano Health, Vacasa, Organogenesis, And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded higher, with the Nasdaq surging more than 500 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
EQRx Provides Portfolio and U.S. Commercial Strategy Updates; Reports Third Quarter 2022 Financial Results
From EQRx, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.